Better outcomes through a more personalized approach.

At Roche Diabetes Care we provide a holistic, therapeutic approach called integrated Personalized Diabetes Management (iPDM). Our approach strengthens the patient care process by integrating digital solutions that quickly turn data into meaningful insights. And, we do this to facilitate stronger communication and collaboration between HCP and patient for more timely treatment decisions.

Clinical studies have demonstrated improved outcomes with the use of solutions similar to RocheDiabetes Care Platform that enable iPDM.

PDM-ProValue Study Program1

Prospective, cluster-randomized, controlled interventional study program

Implementing Integrated Personalized Diabetes Management (iPDM), a structured and digitally supported approach to guide the therapy process through collaborative decisions between physicians and patients with type 2 diabetes, are associated with in significant improvements in glycemic control.

Improvement in glycemic control



  • After 12 months, improvement in glycemic control
    (HbA1c reduction) was greater in the iPDM group
  • Rapid HbA1c reduction followed by stabilization


Earlier and more frequent insulin therapy adjustments

Recommendations for change of QAD, insulin and therapy regimen

  • Percentage of patients with recommended overall changes in medication (comprising oral antidiabetic medication and insulin regimen) was significantly higher in the iPDM group than the control group


Summary of results

Implementing iPDM, a structured and digitally supported approach to guide the therapy process through collaborative decisions between physicians and patients with type 2 diabetes, are associated with significant improvements in glycemic control.


  • Highly significant and clinically relevant HbA1c reductions in patients following the iPDM process

  • According to physicians, the process enabled timely therapy action, which may have resulted in early improvements in glycemic control

  • A more holistic and supportive use of data sources facilitated in the iPDM process may have resulted in better informed therapy decisions

  • Physicians perceived the iPDM process as more structured and customizable, thus facilitating even more personalisation of therapy, and potentially enhancing physician-patient interactions

PDM Connect2

Interventional single arm virtual study

Use of the AccuChek® Connect diabetes management system is associated with increased treatment satisfaction, reduced distress and improved glycemic control among individuals with insulin-treated diabetes.

Change in diabetes treatment satisfaction (DTSQ)



  • High treatment satisfaction was seen at baseline (DTSQs):
    29.8±5.8 on a scale of 0-36 (0=very dissatisfied, 36=very satisfied)


Change in diabetes-related distress



  • Reductions in total mean DDS scores from baseline to 6 months were observed


Change in HbA1c: all and by practice type



  • Significant reductions in mean HbA1c levels from baseline to 6 months were observed



Prospective, comparative, virtual study

Use of diabetes management software by HCPs, patients, and caregivers improves accuracy and efficiency in glucose data interpretation compared with traditional logbook data.

Improved accuracy using diabetes software



  • PWD, CGV and HCP participants achieved greater accuracy using diabetes management software reports vs. logbook data


Reduced time reviewing diabetes information



  • Participants spent less time (minutes) with each case using diabetes management software reports vs. Logbook data


Summary of results

Even without prior routine use of diabetes management software, patients, caregivers and healthcare providers:


  • Identified and utilised key diabetes information and glycemic patterns with significantly greater accuracy and with less time using software reports compared to standard logbooks

  • Expressed a stronger preference for using diabetes software reports vs. traditional logbooks

  • Greater than 90% of study PWD/CVG participants agreed that the AccuChek® Connect Online reports would facilitate more helpful diabetes discussions; 97% of HCP participants agreed that the reports would optimize time during patient consultations


Multicenter prospective observational study

Use of pattern management with the AccuChek® Smart Pix system is associated with a lower HbA1c in a primary care setting.

Improvement of medical outcome: HBA1C

Mean HbA1c over time



  • HbA1c Trend: T1DM Patient Group (N=248)
  • Significant (p<0.0001) and clinically relevant HbA1c decrease for both T1DM and T2DM patients




  • HbA1c Trend: T2DM Patient Group (n=666)
  • Sustained decrease in mean HbA1c for both patient groups


Improvement of process and outcome quality

According to physicians’ opinion:

Usefulness of the Accu-Chek Smart Pix system for therapy decisions (T1DM and T2DM)



  • Time need for therapy decision was reduced in ca. 61% of patient cases
  • Quality of the therapy decision process was improved in ca. 79% of patient cases


Usefulness of the Accu-Chek Smart Pix system as an integral part of patient dialogue (T1DM and T2DM)



  • Communication with patients was improved in ca. 76% cases
  • 61% were more compliant with regard to therapy recommendations
  • 64% conducted SMBG in a more structured way

Values show are rounded

*Patients assessed by physicians


Summary of results

The use of the Accu-Chek Smart Pix system was found to be a valuable part of diabetes management in “real world” practice settings within the study. It was associated with:

  • Significant and clinically relevant HbA1c reductions sustained over time

  • Improved quality of therapy decision process with less time required by participating physicians

  • Helped facilitate the dialogue with the patient and improved patient compliance by participating patients

  • Physicians’ desired to continue their use of the Accu-Chek Smart Pix system in 4 of 5 patients


12-month, cluster multicenter study

Collaborative use of structured blood glucose testing supports significant improvement in patients’ glycemic control, and enables clinicians to increase frequency of treatment adjustments to support better diabetes management.

Improved glycemic control

Structured testing and the AccuChek 360º View tool support reduction of HbA1c when used collaboratively with patients.



Intent-to-treat analysis: Change in mean HbA1c over 12 months


  • Significantly greater HbA1c reduction over time in STG patients (n=256) compared with ACG patients (n=227)
  • Structured testing intervention helped to improve HbA1c values more than the control group


Structured testing and collaborative use of the tool supported reduced postprandial excursions and better overall glycemic control.




Intent-to-treat analysis: Comparison of 7-point glucose profiles at baseline and 12 months (STG)


  • STG patient profiles showed lower average preprandial, postprandial and bedtime glucose levels (p<0.01) from month 1 to month 12
  • STG patients significantly lowered mean postprandial glucose excursions at all meals


Therapy optimization6

Structured testing and the use of the AccuChek 360º View tool enables physicians to make early and systematic therapy changes, resulting in better glycemic control.



  • Patients who received a treatment change recommendation, such as a drug and/or lifestyle change at the Month 1 visit experienced significantly greater reductions in HbA1c
  • For the entire study, out of 5 possible visits, STG patients received therapy change recommendations at 2.7 visits, while ACG patients received therapy change recommendations at 1.1 visits


Summary of results

  • This study revealed that collaborative use of the AccuChek 360° View tool between non-insulin treated T2DM patients and the physician supports reduction of HbA1c and better overall glycemic control

  • The appropriate use of the 3-day profile structured testing tool further enables physicians to make more timely and aggressive treatment changes, resulting in better glycemic control

  • Furthermore, patients in both groups displayed a significant improvement in well-being

clinical outcomes

  • Reduced therapeutic inertia 1-4
  • Improved A1C with no increase in hypoglycaemia. 1,3,4
  • Less glycemic variability. 3,4
  • Better postprandial control. 3,4

Efficient and
effective processes

  • More frequent and timely therapy adjustments. 1-5
  • Faster and more accurate decision-making. 6
  • Greater clinician efficiency. 1,3,6
  • Greater clinician satisfaction. 1,3,5

Stronger HCP and
patient collaboration

  • Higher treatment satisfaction. 1-3
  • Improved therapy adherence. 1,3
  • Enhanced patient understanding. 3,6
  • Improved patient self-efficacy 7

1. Kulzer B, et al. Diabetes Res Clin Pract. 2018;144:200-212; 2. Mora P, et al. Diabetes Technol Ther 2017;19(12): 715-722; 3. Weissmann J, et al. J Diabetes Sci Technol 2016;10(1):76–84; 4. Polonsky WH,et al. Diabetes Care 2011;34(2):262–267; 5. Brotons C., et al. Poster session presented at: ATTD; 2012 February 8-11; Barcelona, Spain; 6. Hinnen DA, et al. J Diabetes Sci Technol 2015;9(2):293-301. 7. Kulzer B et al. Diabetes Stoffwechsel Herz 2019; 28:325-337.